EVs can support breast cancer chemoresistance through different mechanisms, including drug efflux, transfer of ABC transporters, prosurvival signaling molecules, and drug-metabolizing enzymes from resistant to nonresistant cells [85, 86]. This evidence concerns the gene ABCG2 and breast carcinoma.